deucravacitinib
bms
['psoriasis', 'deucrava', 'deucra', 'bristol']
the #fda has approved bristol myers squibb's #deucravacitinib for the treatment of moderate-to-severe plaque #psoriasis. 
Dermatology Times: The latest news and trends in dermatologic procedures, therapy, technology, products and drugs.